Composite Endpoints in Clinical Trials

Peter C. O'Brien, Peter J Dyck, Barbara C. Tilley

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Composite endpoints have become increasingly useful as a measure of a patient's disease status. They have been found useful in both clinical practice and medical research. This chapter examines the usefulness of composite endpoints as a primary endpoint in clinical trials. The basic rationale for their use is discussed and illustrated with examples, followed by a variety of procedures for forming composites including how they should be interpreted. The chapter considers alternate approaches to conducting a primary analysis with multiple endpoints, and compares these methods with the use of composite endpoints. It focuses on the outcome measures used in the typical phase III clinical trial for efficacy, for simplicity assuming that an experimental therapy is being compared with a placebo. Some useful methods for defining a composite endpoint for use as a primary endpoint in a clinical trial are considered.

Original languageEnglish (US)
Title of host publicationConcepts, Principles, Trials, and Designs
Publisherwiley
Pages246-251
Number of pages6
Volume1
ISBN (Electronic)9781118596005
ISBN (Print)9781118595923
DOIs
StatePublished - Sep 26 2014

Fingerprint

Clinical Trials
Phase III Clinical Trials
Investigational Therapies
Biomedical Research
Placebos
Outcome Assessment (Health Care)

Keywords

  • Cardiovascular disease (CVD)
  • Clinical trials
  • Composite endpoints
  • Phase III clinical trial

ASJC Scopus subject areas

  • Medicine(all)

Cite this

O'Brien, P. C., Dyck, P. J., & Tilley, B. C. (2014). Composite Endpoints in Clinical Trials. In Concepts, Principles, Trials, and Designs (Vol. 1, pp. 246-251). wiley. https://doi.org/10.1002/9781118596005.ch21

Composite Endpoints in Clinical Trials. / O'Brien, Peter C.; Dyck, Peter J; Tilley, Barbara C.

Concepts, Principles, Trials, and Designs. Vol. 1 wiley, 2014. p. 246-251.

Research output: Chapter in Book/Report/Conference proceedingChapter

O'Brien, PC, Dyck, PJ & Tilley, BC 2014, Composite Endpoints in Clinical Trials. in Concepts, Principles, Trials, and Designs. vol. 1, wiley, pp. 246-251. https://doi.org/10.1002/9781118596005.ch21
O'Brien PC, Dyck PJ, Tilley BC. Composite Endpoints in Clinical Trials. In Concepts, Principles, Trials, and Designs. Vol. 1. wiley. 2014. p. 246-251 https://doi.org/10.1002/9781118596005.ch21
O'Brien, Peter C. ; Dyck, Peter J ; Tilley, Barbara C. / Composite Endpoints in Clinical Trials. Concepts, Principles, Trials, and Designs. Vol. 1 wiley, 2014. pp. 246-251
@inbook{e5c2169b4709459ab9284d43746777c1,
title = "Composite Endpoints in Clinical Trials",
abstract = "Composite endpoints have become increasingly useful as a measure of a patient's disease status. They have been found useful in both clinical practice and medical research. This chapter examines the usefulness of composite endpoints as a primary endpoint in clinical trials. The basic rationale for their use is discussed and illustrated with examples, followed by a variety of procedures for forming composites including how they should be interpreted. The chapter considers alternate approaches to conducting a primary analysis with multiple endpoints, and compares these methods with the use of composite endpoints. It focuses on the outcome measures used in the typical phase III clinical trial for efficacy, for simplicity assuming that an experimental therapy is being compared with a placebo. Some useful methods for defining a composite endpoint for use as a primary endpoint in a clinical trial are considered.",
keywords = "Cardiovascular disease (CVD), Clinical trials, Composite endpoints, Phase III clinical trial",
author = "O'Brien, {Peter C.} and Dyck, {Peter J} and Tilley, {Barbara C.}",
year = "2014",
month = "9",
day = "26",
doi = "10.1002/9781118596005.ch21",
language = "English (US)",
isbn = "9781118595923",
volume = "1",
pages = "246--251",
booktitle = "Concepts, Principles, Trials, and Designs",
publisher = "wiley",

}

TY - CHAP

T1 - Composite Endpoints in Clinical Trials

AU - O'Brien, Peter C.

AU - Dyck, Peter J

AU - Tilley, Barbara C.

PY - 2014/9/26

Y1 - 2014/9/26

N2 - Composite endpoints have become increasingly useful as a measure of a patient's disease status. They have been found useful in both clinical practice and medical research. This chapter examines the usefulness of composite endpoints as a primary endpoint in clinical trials. The basic rationale for their use is discussed and illustrated with examples, followed by a variety of procedures for forming composites including how they should be interpreted. The chapter considers alternate approaches to conducting a primary analysis with multiple endpoints, and compares these methods with the use of composite endpoints. It focuses on the outcome measures used in the typical phase III clinical trial for efficacy, for simplicity assuming that an experimental therapy is being compared with a placebo. Some useful methods for defining a composite endpoint for use as a primary endpoint in a clinical trial are considered.

AB - Composite endpoints have become increasingly useful as a measure of a patient's disease status. They have been found useful in both clinical practice and medical research. This chapter examines the usefulness of composite endpoints as a primary endpoint in clinical trials. The basic rationale for their use is discussed and illustrated with examples, followed by a variety of procedures for forming composites including how they should be interpreted. The chapter considers alternate approaches to conducting a primary analysis with multiple endpoints, and compares these methods with the use of composite endpoints. It focuses on the outcome measures used in the typical phase III clinical trial for efficacy, for simplicity assuming that an experimental therapy is being compared with a placebo. Some useful methods for defining a composite endpoint for use as a primary endpoint in a clinical trial are considered.

KW - Cardiovascular disease (CVD)

KW - Clinical trials

KW - Composite endpoints

KW - Phase III clinical trial

UR - http://www.scopus.com/inward/record.url?scp=85018842515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018842515&partnerID=8YFLogxK

U2 - 10.1002/9781118596005.ch21

DO - 10.1002/9781118596005.ch21

M3 - Chapter

AN - SCOPUS:85018842515

SN - 9781118595923

VL - 1

SP - 246

EP - 251

BT - Concepts, Principles, Trials, and Designs

PB - wiley

ER -